Insider Stock Trading History of Sharp Shalini


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Sharp Shalini since year 2005. The trader's CIK number is 1377202. At the time of this reporting, Sharp Shalini is the CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc. . (stock ticker symbol RARE). See this page for all insider trading activities at Ultragenyx Pharmaceutical Inc. .

Note that in the past Sharp Shalini also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Sharp Shalini since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-03-02 RARE Ultragenyx Pharmaceutical Inc. Sale 12,000 90.10 1,081,176
2017-03-02 RARE Ultragenyx Pharmaceutical Inc. Option Ex 12,000 .81 9,780
2017-02-27 RARE Ultragenyx Pharmaceutical Inc. Option Ex 12,000 .81 9,780
2017-02-27 RARE Ultragenyx Pharmaceutical Inc. Sale 12,000 80.14 961,680
2017-02-27 RARE Ultragenyx Pharmaceutical Inc. Option Ex 12,000 .81 9,780
2017-02-27 RARE Ultragenyx Pharmaceutical Inc. Sale 12,000 80.14 961,680
2016-12-23 RARE Ultragenyx Pharmaceutical Inc. Option Ex 6,500 .81 5,265
2016-11-09 RARE Ultragenyx Pharmaceutical Inc. Option Ex 24,000 .81 19,560
2016-11-09 RARE Ultragenyx Pharmaceutical Inc. Sale 24,000 72.51 1,740,192
2016-10-19 RARE Ultragenyx Pharmaceutical Inc. Sale 12,000 61.34 736,140
2016-10-19 RARE Ultragenyx Pharmaceutical Inc. Option Ex 12,000 .81 9,780
2015-12-10 RARE Ultragenyx Pharmaceutical Inc. Option Ex 12,000 .81 9,780
2015-12-10 RARE Ultragenyx Pharmaceutical Inc. Sale 12,000 101.59 1,219,140
2015-07-20 RARE Ultragenyx Pharmaceutical Inc. Sale 3,854 131.67 507,467
2015-07-20 RARE Ultragenyx Pharmaceutical Inc. Sale 3,854 131.67 507,467
2015-06-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 96.15 384,600
2015-05-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 79.43 317,720
2015-05-01 RARE Ultragenyx Pharmaceutical Inc. Option Ex 1,000 .81 815
2015-04-20 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 61.87 247,460
2015-03-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 61.45 245,800
2015-02-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 54.32 217,284
2015-01-20 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 51.24 204,956
2014-12-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 44.82 179,288
2014-11-20 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 44.07 176,280
2014-10-20 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 46.02 184,080
2014-09-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 56.00 224,000
2014-08-18 RARE Ultragenyx Pharmaceutical Inc. Sale 4,000 53.97 215,880
2014-01-30 RARE Ultragenyx Pharmaceutical Inc. Buy 4,500 21.00 94,500
2013-01-30 AGEN Antigenics Inc /de/ Sale 288 4.36 1,255
2012-10-31 AGEN Antigenics Inc /de/ Sale 288 4.40 1,267
2012-08-29 AGEN Antigenics Inc /de/ Sale 288 4.64 1,336
2011-12-27 AGEN Antigenics Inc /de/ Sale 2,853 2.14 6,105
2011-12-28 AGEN Antigenics Inc /de/ Sale 1,711 2.09 3,575
2011-12-21 AGEN Antigenics Inc /de/ Sale 3,087 2.24 6,908
2011-12-23 AGEN Antigenics Inc /de/ Sale 795 2.20 1,746
2011-12-22 AGEN Antigenics Inc /de/ Sale 1,548 2.19 3,390
2010-10-28 AGEN Antigenics Inc /de/ Sale 1,500 .96 1,440
2010-09-14 AGEN Antigenics Inc /de/ Sale 2,000 .91 1,824
2010-07-27 AGEN Antigenics Inc /de/ Sale 1,520 .93 1,407
2010-04-27 AGEN Antigenics Inc /de/ Sale 1,950 1.16 2,262
2010-01-20 AGEN Antigenics Inc /de/ Sale 63,848 .85 54,462
2009-07-15 AGEN Antigenics Inc /de/ Sale 13,271 1.76 23,396
2009-07-16 AGEN Antigenics Inc /de/ Sale 32,525 1.62 52,625
2007-03-12 AGEN Antigenics Inc /de/ Buy 5,000 1.95 9,735
2007-03-13 AGEN Antigenics Inc /de/ Buy 5,000 1.97 9,835

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sharp Shalini (CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.